Benzinga | Jan 12, 2021 08:08AM EST

Surmodics Reports TRANSCEND Trial 12-Month Data To Be Presented At Leipzig Interventional Course Event Jan. 25

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 12-month data from its TRANSCEND clinical trial will be presented at the upcoming Leipzig Interventional Course (LINC) 2021 virtual event. Dr. Kenneth Rosenfield, a principal investigator of the TRANSCEND study, will present as part of a January 25 late-breaking trial session on new data and innovative concepts for treatment of femoral arteries. Preliminary schedule details are provided below:

Results of the TRANSCEND study ? the randomized and controlled noninferiority trial to evaluate safety and clinical efficacy of theTITLE: SurVeil? drug-coated balloon compared to IN.PACT(R) Admiral(R) drug-coated balloon in the treatment of femoropopliteal artery disease.

SPEAKER: Dr. Kenneth Rosenfield

SESSION: LATE BREAKING TRIAL SESSION: New data and innovative concepts for treatment of femoral arteries ? part I

DATE/ January 25, 2021TIME:

Session - 6:15 a.m. to 7:10 a.m. (CST)

TRANSCEND trial presentation - 6:45 a.m. to 6:50 a.m. (CST)